Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abediterol
Другие языки:

Abediterol

Подписчиков: 0, рейтинг: 0
Abediterol
Abediterol.svg
Clinical data
Routes of
administration
Inhalation
ATC code
  • None
Pharmacokinetic data
Elimination half-life 24.3 hours
Identifiers
  • 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C25H30F2N2O4
Molar mass 460.522 g·mol−1
3D model (JSmol)
  • FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
  • InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 checkY
  • Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N checkY

Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.

It acts as a dual β2 adrenergic agonist and muscarinic antagonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA).

Its coformulation with mometasone furoate is also in Phase II clinical trials.


Новое сообщение